> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Companies Recalling More Kogenate/Helixate FS Lots
- URL: https://www.fdaweb.com/companies-recalling-more-kogenate-helixate-fs-lots/
- Published: 2016-08-24T12:00:00.000Z
- Updated: 2026-09-14T21:26:39.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5136598

FDA says that Bayer has expanded its 7/21 recall of two lots of its hemophilia A drug Kogenate FS containing active ingredient manufactured before 11/2015 to include eight additional lots. An agency [notice](http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/Recalls/ucm517465.htm?ref=fdaweb.com) says the recall expansion is based on a company analysis of additional lots with active ingredient manufactured before 11/2015 to determine a need for further action.

“Routine stability testing showed potency is declining faster than expected in these lots, which is why the recall is being conducted,” FDA says.

In a related [notice](http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/Recalls/ucm517460.htm?ref=fdaweb.com), FDA says that CSL Behring has expanded its initial recall of two lots of its hemophilia A drug Helixate FS containing active ingredient manufactured before 11/2015 and has added 40 additional lots.